search

Active clinical trials for "Uveomeningoencephalitic Syndrome"

Results 1-10 of 12

Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)

Diabetic Macular EdemaVogt Koyanagi Harada Disease1 more

Suprachoroidal drug delivery is a recent route for managing various ocular conditions. Safety and long term results are still under investigations.

Recruiting6 enrollment criteria

A Study of Mycophenolate Mofetil Combined With Glucocorticoid Therapy in Relapse Vogt-Koyanagi-Harada...

Vogt-Koyanagi-Harada DiseaseMycophenolate Mofetil

This project is designed to test the hypothesis that Mycophenolate Mofetil is clinically useful for patients with relapse Vogt-Koyanagi-Harada disease

Recruiting9 enrollment criteria

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

Vogt-Koyanagi-Harada DiseaseAdalimumab

This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease

Recruiting12 enrollment criteria

Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease

Vogt Koyanagi Harada Disease

This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subclinical signs of disease activity added with electroretinogram exams, through predefined intervals, will be evaluated through a minimum 12-month follow-up.

Recruiting3 enrollment criteria

Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH

Vogt Koyanagi Harada Disease (VKH)

The aim of this study is to evaluate the efficacy and safety of corticosteroidcombining noncorticosteroid systemic immunomodulatory therapy (NCSIT) for the treatment of Vogt Koyanagi Harada disease (VKH).

Recruiting8 enrollment criteria

Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment

Vogt Koyanagi Harada Disease

Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection

Completed4 enrollment criteria

Outcome of Treatment of Uveitis With Biologic Drugs in Resistant Cases Vogt-koyanagi-Harada Disease...

Uveitis

Reviewing the characteristics of patients with uveitis caused by Vogt-Koyanagi-Harada Syndrome treated at Assiut University Hospital at the Department of Ophthalmology and Department of Rheumatology, Physical Medicine, and Rehabilitation including the ocular features in terms of uveitis location, type and complications and systemic features of those subjects who showed an inadequate response to conventional immunomodulatory drugs. Assess the results of treatment with biologic drugs, including rates of failure and adverse events. This will help uveitis specialists to reach a conclusion about the best treatment protocols for Uveitis in Vogt-Koyanagi-Harada Syndrome in our population in terms of safety, efficacy, and cost-effectiveness.

Not yet recruiting4 enrollment criteria

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Vogt Koyanagi Harada DiseaseSerpiginous Choroiditis1 more

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Completed6 enrollment criteria

Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I

Uveomeningoencephalitic SyndromeInflammation2 more

Patients with acute onset Vogt-Koyanagi-Harada disease (VKHD) was prospectively included in this study. They were systematically followed with clinical, posterior segment imaging exams and full-field electroretinogram during a minimum 24-month of follow-up. All patients were treated with 3-day methylprednisolone pulse therapy followed by 1mg/day oral prednisone with a slow tapper during a median of 13 months. Non-steroidal immunosuppressive therapy (IMT) was introduced in cases of refractory disease or in cases of prednisone intolerance. Outcome measured by full-field electroretinogram was analyzed and patient was grouped as electroretinogram stable or electroretinogram worsening. Clinical data was analyzed in these two electroretinogram-based groups.

Completed4 enrollment criteria

Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome...

Autoimmune UveitisBehçet Disease6 more

This study aimed to discover the composition on the microbiome in several sites of the human body; and to find out the difference in microbiome composition on ocular fluid, blood, and feces before and after therapy in uveitis patient with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis

Unknown status24 enrollment criteria
12

Need Help? Contact our team!


We'll reach out to this number within 24 hrs